Brixadi Injection
Product Images NDC 58284-216

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Brixadi (NDC 58284-216). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Braeburn Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Brixadi 01)

An instructional diagram labeled 'Safety Syringe: Before Use' showing the components of a safety syringe. The syringe is disassembled into parts with labels pointing to Needle Cap, Syringe Guard Body, Syringe Guard Wings, Plunger, and Plunger Head, illustrating the syringe setup prior to use.*

FDA Label Image

Figure 2 (Brixadi 02)

An instructional diagram titled 'Safety Syringe: After Use (With needle protection mechanism activated)' illustrating a syringe with labeled parts, including the 'Activated Syringe Guard' covering the needle and the 'Plunger Head.' The image demonstrates the syringe with the needle safety feature activated.*

FDA Label Image

Figure 3 (Brixadi 03)

An instructional diagram showing the components of a BRIXADI subcutaneous injection system, including a labeled plunger and a syringe with attached syringe guard, arranged within a molded tray.*

FDA Label Image

Figure 4 (Brixadi 04)

An illustration labeled 'Not included in the carton:' showing three items: an alcohol prep pad in a small packet, a round cotton pad, and a biohazard sharps disposal container with a lid, indicating these items are not included with the product packaging.*

FDA Label Image

Figure 5 (Brixadi 05)

Diagram showing recommended subcutaneous injection sites on an adult human male figure. Front and back views highlight shaded areas including the abdomen, upper arms, upper thighs, and lower back flanks. Used for proper administration of BRIXADI (buprenorphine) injection.*

FDA Label Image

Figure 6 (Brixadi 06)

An instructional diagram showing two stages labeled 'Before' and 'After' of engaging a plunger-like device with a vial or cartridge. The 'Before' panel illustrates pressing down and twisting the plunger, while the 'After' panel displays the plunger fully inserted into the vial, depicting assembly or preparation of an injection device.*

FDA Label Image

Figure 7 (Brixadi 07)

Illustration showing gloved hands preparing a syringe for injection. One hand holds the syringe with needle, the other hand holds an opened vial or container, indicating preparation for a subcutaneous injection.*

FDA Label Image

Figure 8 (Brixadi 08)

Illustration showing a gloved hand pinching skin, demonstrating technique likely related to subcutaneous injection administration.*

FDA Label Image

Figure 9 (Brixadi 09)

Illustration showing the administration of a subcutaneous injection using a prefilled syringe. The syringe is held at a 90-degree angle to the skin, demonstrating proper injection technique with hands in position to inject into the skin fold.*

FDA Label Image

Figure 10 (Brixadi 10)

An instructional illustration showing a hand pressing down on the top of a subcutaneous injection device, with an arrow indicating downward pressure. The diagram appears to demonstrate the proper technique for administering an injection, likely related to the BRIXADI buprenorphine injection device.*

FDA Label Image

Figure 11 (Brixadi 11)

An instructional illustration showing a hand holding an injection device above a forearm. Arrows indicate the direction for pressing the injector down and the injection site on the skin below, demonstrating subcutaneous administration technique.*

FDA Label Image

Figure 12 (Brixadi 12)

An instructional illustration showing a gloved hand holding a syringe with an arrow indicating the direction to pull back the plunger. This image likely demonstrates part of the preparation or administration process for an injection. No specific product labeling or dosing information is visible.*

FDA Label Image

Figure 13 (Brixadi 13)

An illustration showing a gloved hand holding a syringe, positioned above a biohazard sharps disposal container, demonstrating safe injection disposal practices.*

FDA Label Image

Chemical Structure (Brixadi 14)

Chemical structure of buprenorphine, the active ingredient in BRIXADI injection. The diagram shows the molecular configuration with rings, hydroxyl groups, and nitrogen-containing components of the compound.*

FDA Label Image

Figure 14 (Brixadi 15)

A scatter plot showing Placebo-Corrected VAS Drug-Liking Score (mm) on the vertical axis versus Buprenorphine Plasma Concentration (ng/mL) on the horizontal axis. Two data sets are indicated: baseline with no buprenorphine (solid triangles) clustered at zero plasma concentration with high drug-liking scores, and after BRIXADI injection (open circles) spread across various plasma concentrations with generally lower drug-liking scores.*

FDA Label Image

Figure 15 (Brixadi 16)

This line graph compares the least squares mean difference in drug liking (VAS mm) over time before and after doses of BRIXADI injection, showing results for 24 mg and 32 mg weekly subcutaneous doses. The x-axis displays time intervals relative to dosing, and the y-axis measures drug liking with a reference line indicating complete blockade.*

FDA Label Image

Figure 16 (Brixadi 17)

A line graph depicting the least squares mean difference in drug liking (VAS mm) over time relative to doses of BRIXADI. The x-axis shows timepoints: before BRIXADI, 1-3 days and 4-6 days after Dose 1, and 1-3 days and 4-6 days after Dose 2. Two lines represent weekly doses of BRIXADI: 24 mg (black circles and solid line) and 32 mg (gray circles and dashed line). The graph shows a notable decrease in drug liking before the first dose, followed by low and stable values after subsequent doses.*

FDA Label Image

Figure 17 (Brixadi 18)

A line graph comparing the percentage of participants over time in two treatment groups for BRIXADI (buprenorphine injection) and sublingual buprenorphine/naloxone (SL BPN/NX). The x-axis shows the percentage of negative opioid assessments (urine and self-report), and the y-axis shows the percentage of participants. The graph illustrates participant outcomes in these treatments.*

FDA Label Image

Carton (Principal Panel)

BRIXADI 8 mg subcutaneous injection label showing an 8 mg dose of buprenorphine in a 0.16 mL volume of solution. It is a single-dose prefilled syringe kit with a warning about serious harm or death if injected intravenously. The label includes administration instructions, contents, and prescribing information by Braeburn Inc.*

FDA Label Image

Carton (Principal Panel)

BRIXADI 16 mg/0.32 mL extended-release injection for subcutaneous use. The label shows a single-dose prefilled syringe kit containing 16 mg buprenorphine in 0.32 mL of solution. It includes a prefilled syringe, plunger rod, prescribing information, instructions for use, and medication guide. Distributed by Braeburn Inc., this weekly injection is for healthcare provider administration only and not for patient dispensing.*

FDA Label Image

Carton (Principal Panel)

BRIXADI 24 mg extended-release injection for subcutaneous use in a single-dose prefilled syringe kit. The label highlights 24 mg of buprenorphine in 0.48 mL solution, intended for weekly subcutaneous injection. The label includes safety warnings about not injecting intravenously and is distributed by Braeburn Inc.*

FDA Label Image

Carton (Principal Panel)

BRIXADI 32 mg injection, a buprenorphine extended-release formulation for subcutaneous use, displayed on a prefilled syringe kit label. The syringe contains 0.64 mL of solution per dose for weekly administration. Label notes serious harm or death if injected intravenously and specifies single-dose syringe contents and healthcare provider instructions. Distributed by Braeburn Inc.*

FDA Label Image

Carton (Principal Panel)

BRIXADI 64 mg subcutaneous injection, buprenorphine extended-release in a single-dose prefilled syringe kit. The label highlights a 0.18 mL syringe volume of a 356 mg/mL solution, intended for monthly use. Warning statement about serious harm or death if injected intravenously is included. Distributed by Braeburn Inc.*

FDA Label Image

Carton (Principal Panel)

BRIXADI 96 mg/0.27 mL extended-release injection for subcutaneous use, presented in a single-dose prefilled syringe kit. The label highlights the dosage strength and volume, warns against intravenous injection, and includes instructions and prescribing information. Distributed by Braeburn Inc.*

FDA Label Image

Carton (Principal Panel)

BRIXADI 128 mg injection label for subcutaneous use. The product is a single-dose prefilled syringe kit containing 128 mg buprenorphine in 0.36 mL solution. The label includes warnings for serious harm or death if injected intravenously and instructions for healthcare provider administration only. Distributed by Braeburn Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.